Roche: Ocrevus data provide insights into multiple sclerosis
(CercleFinance.com) - Swiss drugmaker Roche has presented new biomarker data that increase understanding of disease progression in multiple sclerosis.
It appears that blood neurofilament light chain (NfL) levels were significantly lowered following Roche's Ocrevus treatment in analyses of Phase III studies in relapsing multiple scelrosis and primary progressive multiple sclerosis (PPMS) patients.
This means that NfL may be a biomarker to predict future disability outcomes, Roche said.
According to the company, these analyses provide new insights, with the goal of identifying and slowing disease progression as early as possible to preserve patient function over the long term.
The data will presented at the upcoming congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) that starts tomorrow.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
It appears that blood neurofilament light chain (NfL) levels were significantly lowered following Roche's Ocrevus treatment in analyses of Phase III studies in relapsing multiple scelrosis and primary progressive multiple sclerosis (PPMS) patients.
This means that NfL may be a biomarker to predict future disability outcomes, Roche said.
According to the company, these analyses provide new insights, with the goal of identifying and slowing disease progression as early as possible to preserve patient function over the long term.
The data will presented at the upcoming congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) that starts tomorrow.
Copyright (c) 2019 CercleFinance.com. All rights reserved.